{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:06:56Z","timestamp":1790888816958,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.vaccine.2024.02.073","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T09:32:16Z","timestamp":1709199136000},"page":"2254-2259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18\u201360\u00a0years: A double-blind, non-inferiority, randomized controlled trial"],"prefix":"10.1016","volume":"42","author":[{"given":"Davood","family":"Yadegarynia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirreza","family":"Keyvanfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Keyvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabnam","family":"Tehrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahnaz","family":"Sali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Abolghasemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2024.02.073_b0005","doi-asserted-by":"crossref","DOI":"10.3390\/v15010116","article-title":"Influenza and universal vaccine research in China","volume":"15","author":"Li","year":"2022","journal-title":"Viruses"},{"issue":"27","key":"10.1016\/j.vaccine.2024.02.073_b0010","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1016\/j.vaccine.2018.05.057","article-title":"Economic burden of seasonal influenza in the United States","volume":"36","author":"Putri","year":"2018","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2024.02.073_b0015","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1111\/jgs.17179","article-title":"Reduction in respiratory viral infections among hospitalized older adults during the COVID-19 pandemic","volume":"69","author":"Tan","year":"2021","journal-title":"J Am Geriatr Soc"},{"issue":"10","key":"10.1016\/j.vaccine.2024.02.073_b0020","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/jama.2021.14131","article-title":"Influenza's unprecedented low profile during COVID-19 pandemic leaves experts wondering what this flu season has in store","volume":"326","author":"Rubin","year":"2021","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.vaccine.2024.02.073_b0025","doi-asserted-by":"crossref","first-page":"e1003550","DOI":"10.1371\/journal.pmed.1003550","article-title":"Global burden of influenza-associated lower respiratory tract infections and hospitalizations among adults: A systematic review and meta-analysis","volume":"18","author":"Lafond","year":"2021","journal-title":"PLoS Med"},{"issue":"6","key":"10.1016\/j.vaccine.2024.02.073_b0030","doi-asserted-by":"crossref","DOI":"10.3390\/v13060971","article-title":"Selecting and using the appropriate influenza vaccine for each individual","volume":"13","author":"Sekiya","year":"2021","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.vaccine.2024.02.073_b0035","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jgr.2022.12.007","article-title":"COVID-19 infection and ginseng: Predictive influenza virus strains and non-predictive COVID-19 vaccine strains","volume":"47","author":"Rhee","year":"2023","journal-title":"J Ginseng Res"},{"key":"10.1016\/j.vaccine.2024.02.073_b0040","article-title":"Recent progress in recombinant influenza vaccine development toward heterosubtypic immune response","volume":"13","author":"Carascal","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2024.02.073_b0045","unstructured":"Salamat, N.P. FluGuard. 2022 19 Oct 2023]; Available from: https:\/\/www.fluguard.ir\/en."},{"issue":"3","key":"10.1016\/j.vaccine.2024.02.073_b0050","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jinf.2021.12.035","article-title":"Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: A systematic literature review and meta-analysis","volume":"84","author":"Marra","year":"2022","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2024.02.073_b0055","unstructured":"Products, C.f.P.M., The European Agency for the Evaluation of Medicinal Products: Human Medicines Evaluation Unit. 1996, in Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses (CPMP\/BWP\/268\/95)."},{"key":"10.1016\/j.vaccine.2024.02.073_b0060","unstructured":"Organization, W.H., Manual for the laboratory diagnosis and virological surveillance of influenza. 2011: World Health Organization."},{"key":"10.1016\/j.vaccine.2024.02.073_b0065","unstructured":"(FDA), F.a.d.A. Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines. 2021; Available from: https:\/\/www.fda.gov\/media\/73706\/download."},{"key":"10.1016\/j.vaccine.2024.02.073_b0070","unstructured":"Food, U. and D. Administration, Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. Food and Drug Administration: Silver Spring, MD, USA, 2007."},{"issue":"25","key":"10.1016\/j.vaccine.2024.02.073_b0075","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa1608862","article-title":"Efficacy of recombinant influenza vaccine in adults 50 years of age or older","volume":"376","author":"Dunkle","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2024.02.073_b0080","doi-asserted-by":"crossref","first-page":"e01996","DOI":"10.1128\/mBio.01996-15","article-title":"Age dependence and isotype specificity of influenza virus hemagglutinin stalk-reactive antibodies in humans","volume":"7","author":"Nachbagauer","year":"2016","journal-title":"MBio"},{"issue":"6","key":"10.1016\/j.vaccine.2024.02.073_b0085","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1750-2659.2008.00053.x","article-title":"FluBlok, a recombinant hemagglutinin influenza vaccine","volume":"2","author":"Cox","year":"2008","journal-title":"Influenza Other Respir Viruses"},{"issue":"3","key":"10.1016\/j.vaccine.2024.02.073_b0090","doi-asserted-by":"crossref","first-page":"e2332","DOI":"10.1002\/rmv.2332","article-title":"Systematic review of the efficacy, effectiveness and safety of cell-based seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals \u226518 years of age","volume":"33","author":"Jordan","year":"2023","journal-title":"Rev Med Virol"},{"issue":"35","key":"10.1016\/j.vaccine.2024.02.073_b0095","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1016\/j.vaccine.2016.06.064","article-title":"Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and meta-analysis of randomised controlled trials","volume":"34","author":"Moa","year":"2016","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2024.02.073_b0100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.vaccine.2012.10.084","article-title":"Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials","volume":"31","author":"DiazGranados","year":"2012","journal-title":"Vaccine"},{"issue":"48","key":"10.1016\/j.vaccine.2024.02.073_b0105","doi-asserted-by":"crossref","first-page":"6622","DOI":"10.1016\/j.vaccine.2015.10.097","article-title":"Randomized comparison of the safety of Flublok(\u00ae) versus licensed inactivated influenza vaccine in healthy, medically stable adults \u2265 50 years of age","volume":"33","author":"Izikson","year":"2015","journal-title":"Vaccine"}],"updated-by":[{"DOI":"10.1016\/j.vaccine.2026.128881","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000}}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24002494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24002494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T19:30:19Z","timestamp":1723059019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24002494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0264410X24002494"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.02.073","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18\u201360\u00a0years: A double-blind, non-inferiority, randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.02.073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}